Suraksha Diagnostic Ltd

SURAKSHA

Watchlist

AI Mode

‌

Market Cap

₹ 1,485 Cr

P/E

46.53

‌

Investment Checklist

How to read checklist?

Performance

UNDER PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

HIGH RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Suraksha Diagnostic Limited is a leading diagnostic services provider in East India, focusing on thorough pathological and radiological testing.

In Q2 FY26, they posted a 17% YoY revenue growth, driven by expansion and new service lines, reaching ₹796 million in revenue.

The company expanded its reach by adding five new diagnostic centers, taking the total count to 63, and launched a genomics vertical.

Strategically, they've acquired a majority stake in Fetomat Wellness, enhancing their fetal and maternal diagnostic capabilities.

Their medium-term vision is to become the premier diagnostic facility in India, leveraging technological advancements for diagnostic precision and customer satisfaction.

Sector

Healthcare

Industry

Diagnostic Services

Market Cap

1,485 Cr

Volatility

Moderate Risk

P/E Ratio

46.5

Industry P/E

48.3

PEG Ratio

2.1

P/B Ratio

6.5

52W High

445.90

52W Low

233.15

Sales CAGR

15.26%

3.73%

—

10Y

—

Profit CAGR

33.94%

12.08%

—

10Y

—

ROE

TTM

13.86%

11.78%

11.50%

10Y

—

ROCE

TTM

14.74%

13.81%

13.74%

10Y

—

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
VIMTALABS	611.90	2,719 Cr	44.73	7.93	0.16	14.59	19.04	13.94
KRSNAA	742.75	2,428 Cr	28.71	2.63	0.37	9.16	11.09	5.61
SURAKSHA	285.60	1,485 Cr	46.53	6.45	0.00	13.86	14.74	8.19
ONEGLOBAL	606.65	1,186 Cr	27.02	11.70	0.00	43.51	58.07	19.53
CHANDAN	293.90	719 Cr	32.40	5.86	0.00	19.63	21.52	10.52
QLL	400.00	466 Cr	74.07	3.36	0.00	0.00	0.00	2.06
STARIMAGIN	104.15	182 Cr	11.45	1.77	0.00	18.49	23.03	13.19

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	60	52	55	61	67	60	65	73	79
Expenses	39	37	36	40	44	41	46	49	55
Operating Profit	21	15	19	21	23	18	19	24	24
OPM %	34.70	29.54	35.28	33.92	34.74	30.68	29.47	32.72	30.62
Other Income	0.56	0.85	0.20	1.12	1.31	0.60	0.82	0.91	0.85
Interest	2.48	2.03	2.08	2.22	2.13	1.98	2.06	2.70	2.78
Depreciation	7.95	7.92	8.36	8.99	8.75	8.83	8.73	9.48	10
Profit Before Tax	11	6.22	9.23	11	14	8.05	9.21	12	12
Tax %	23.97	27.01	31.53	27.12	25.53	25.59	22.15	26.38	26.72
Net Profit	8.34	4.54	6.32	7.67	10	5.98	7.17	9.18	8.83
EPS in Rs	—	—	—	—	—	1.18	1.42	1.80	1.73

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	140	223	190	219	252	264
Expenses	118	175	146	149	171	180
Operating Profit	22	48	44	70	81	84
OPM %	15.91	21.54	23.10	32.04	32.23	31.97
Other Income	1.38	2.30	3.55	2.77	3.85	3.64
Interest	1.56	2.10	9.06	8.79	8.39	8.87
Depreciation	16	15	32	33	35	36
Profit Before Tax	6.37	33	6.75	31	41	43
Tax %	-0.96	28.45	10.12	26.47	25.18	25.07
Net Profit	6.44	24	6.07	23	31	32
EPS in Rs	—	—	—	—	—	6.13
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.90	6.90	6.90	6.90	10
Reserves	118	141	147	171	201
Borrowings	18	104	99	92	89
Other Liabilities	28	32	28	30	33
Total Liabilities	171	284	281	300	334
Fixed Assets	119	207	195	212	223
CWIP	0.16	1.24	2.39	1.31	11
Investments	5.41	0.00	0.00	0.00	1.00
Other Assets	46	76	84	87	99
Total Assets	171	284	281	300	334

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	24	42	44	60	63
Cash from Investing Activity	-28	-44	-21	-35	-40
Cash from Financing Activity	3.21	1.09	-24	-25	-24
Net Cash Flow	-0.99	-0.36	-1.03	0.36	-0.27

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jul 2024	Nov 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	72.41%	100.00%	48.78%	48.78%	48.88%	48.98%
FIIs	0.00%	0.00%	15.64%	14.46%	13.95%	13.72%
DIIs	27.59%	0.00%	16.68%	22.05%	22.37%	21.98%
Public	0.00%	0.00%	18.89%	14.70%	14.80%	15.31%
Total Shareholders	10	10	1,33,085	87,275	79,670	75,304

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Dec 10, 2025	Bipul mittal huf	Insider - Promoter Group	Acquisition	274.70	0.04 Cr	1,445	0.00
Dec 10, 2025	Bipul mittal	Insider - Promoters Immediate Relative	Acquisition	274.32	0.16 Cr	5,800	0.01
Sep 29, 2025	Ritu mittal	Insider - Promoter & Director	Acquisition	301.69	0.58 Cr	19,130	0.03
Aug 18, 2025	Dr. somnath chatterjee	Insider - Promoter & Director	Acquisition	317.28	0.25 Cr	7,800	0.01
Aug 14, 2025	Dr. somnath chatterjee	Insider - Promoter & Director	Acquisition	302.41	0.25 Cr	8,200	0.01
Aug 13, 2025	Dr. somnath chatterjee	Insider - Promoter & Director	Acquisition	300.91	0.25 Cr	8,235	0.01
Aug 13, 2025	Dr. somnath chatterjee	Insider - Promoter & Director	Acquisition	302.53	0.25 Cr	8,190	0.01
Jun 25, 2025	Dr. somnath chatterjee	Insider - Promoter & Director	Acquisition	331.90	0.25 Cr	7,450	0.01
Jun 20, 2025	Bipul mittal	Insider - Promoters Immediate Relative	Acquisition	326.14	0.50 Cr	15,260	—
Jun 20, 2025	Bipul mittal huf	Insider - Promoter Group	Acquisition	325.68	0.50 Cr	15,275	—

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q2 FY25

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

Suraksha Diagnostic Limited is a leading diagnostic services provider in East India, focusing on thorough pathological and radiological testing.

In Q2 FY26, they posted a 17% YoY revenue growth, driven by expansion and new service lines, reaching ₹796 million in revenue.

The company expanded its reach by adding five new diagnostic centers, taking the total count to 63, and launched a genomics vertical.

Strategically, they've acquired a majority stake in Fetomat Wellness, enhancing their fetal and maternal diagnostic capabilities.

Their medium-term vision is to become the premier diagnostic facility in India, leveraging technological advancements for diagnostic precision and customer satisfaction.

Sector

Healthcare

Industry

Diagnostic Services

Market Cap

1,485 Cr

Volatility

Moderate Risk

P/E Ratio

46.5

Industry P/E

48.3

PEG Ratio

2.1

P/B Ratio

6.5

52W High

445.90

52W Low

233.15

Sales CAGR

15.26%

3.73%

—

10Y

—

Profit CAGR

33.94%

12.08%

—

10Y

—

ROE

TTM

13.86%

11.78%

11.50%

10Y

—

ROCE

TTM

14.74%

13.81%

13.74%

10Y

—